Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.
Loader

Loading Pathway...

GTPase HRas Dual specificity mitogen- activated protein kinase kinase 1 Dual specificity mitogen- activated protein kinase kinase 2 Mast/stem cell growth factor receptor Kit Fms-related tyrosine kinase 3 ligand Sphingosine kinase 2 GTPase HRas Vascular endothelial growth factor A Vascular endothelial growth factor C Vascular endothelial growth factor B Vascular endothelial growth factor D AKT1 Dual specificity mitogen- activated protein kinase kinase 1 Platelet- derived growth factor DD Platelet- derived growth factor BB Solute carrier family 22 member 1 Solute carrier family 22 member 1 Son of sevenless homolog 1 Growth factor receptor-bound protein 2 RAF1 BRAF ARAF FL cytokine receptor Son of sevenless homolog 1 Growth factor receptor-bound protein 2 Vascular endothelial growth factor receptor 2 Protein kinase C alpha type RAF1 BRAF ARAF Vascular endothelial growth factor receptor 3 Protein kinase C alpha type Vascular endothelial growth factor receptor 1 Protein kinase C alpha type Platelet- derived growth factor receptor beta Son of sevenless homolog 1 PI3K Sorafenib Sorafenib Sorafenib Phosphate Zinc Zinc Mast/stem cell growth factor receptor Cellular Proliferation and Replication Apoptosis Activation of Transcription Factors AKT Pathway Apoptosis Magnesium Tumor Cell Cytosol Endothelial Cell Nucleus Sorabenib inhibits cell surface kinases c-KIT and FLT-3 on tumor cells and further inhibits it's signalling as a result. Sorafenib also inhibits the RAF1 protein. Because the RAF1 protein inhibits apoptosis , the inhibition of RAF1 allows apoptosis to occur killing the tumor cell. Through inhibition of the RAF1 protein and the tyrosine kinase receptors c-KIT and FLT-3, RAS signalling is stopped so cellular proliferation and replication is inhibited as well downstream. This is ideal for tumor cells as their quick proliferation can be stopped. Sorafenib also inhibits the RAF1 protein. Because the RAF1 protein inhibits apoptosis , the inhibition of RAF1 allows apoptosis to occur for the endothelial cells around the tumor. This cuts off blood supply to the tumor. Through inhibition of the RAF1 protein and the tyrosine kinase receptors c-KIT and FLT-3, RAS signalling is stopped so cellular proliferation and replication is inhibited as well downstream. This also prevents angiogenesis preventing blood from being delivered to the tumor. Sorafenib is absorbed through the GI tract into the blood where it enters the endothelial cells and tumor cells..
Nucleus HRAS MAP2K1 MAP2K2 KIT FLT3LG SPHK2 HRAS VEGFA VEGFC VEGFB VEGFD AKT1 MAP2K1 PDGFD PDGFB SLC22A1 SLC22A1 SOS1 GRB2 Unknown BRAF ARAF FLT3 SOS1 GRB2 KDR PRKCA Unknown BRAF ARAF FLT4 PRKCA FLT1 PRKCA PDGFRB SOS1 PIK3CA Sorafenib Sorafenib Sorafenib KIT Cellular Proliferation and Replication Apoptosis Activation of Transcription Factors AKT Pathway Apoptosis
HRAS MAP2K1 MAP2K2 KIT FLT3LG SPHK2 HRAS VEGFA VEGFC VEGFB VEGFD AKT1 MAP2K1 PDGFD PDGFB SLC22A1 SLC22A1 SOS1 GRB2 BRAF ARAF FLT3 SOS1 GRB2 KDR PRKCA BRAF ARAF FLT4 PRKCA FLT1 PRKCA PDGFRB SOS1 PIK3CA Sfib Sfib Sfib Pi Zinc Zinc KIT C P a R Apopt A o T F AKT Pat Apopt Mg2+ Tumor Cell Cytosol Endothelial Cell Nucleus Sorabenib inhibits cell surface kinases c-KIT and FLT-3 on tumor cells and further inhibits it's signalling as a result. Sorafenib also inhibits the RAF1 protein. Because the RAF1 protein inhibits apoptosis , the inhibition of RAF1 allows apoptosis to occur killing the tumor cell. Through inhibition of the RAF1 protein and the tyrosine kinase receptors c-KIT and FLT-3, RAS signalling is stopped so cellular proliferation and replication is inhibited as well downstream. This is ideal for tumor cells as their quick proliferation can be stopped. Sorafenib also inhibits the RAF1 protein. Because the RAF1 protein inhibits apoptosis , the inhibition of RAF1 allows apoptosis to occur for the endothelial cells around the tumor. This cuts off blood supply to the tumor. Through inhibition of the RAF1 protein and the tyrosine kinase receptors c-KIT and FLT-3, RAS signalling is stopped so cellular proliferation and replication is inhibited as well downstream. This also prevents angiogenesis preventing blood from being delivered to the tumor. Sorafenib is absorbed through the GI tract into the blood where it enters the endothelial cells and tumor cells..
Nucleus HRAS MAP2K1 MAP2K2 KIT FLT3LG SPHK2 HRAS VEGFA VEGFC VEGFB VEGFD AKT1 MAP2K1 PDGFD PDGFB SLC22A1 SLC22A1 SOS1 GRB2 BRAF ARAF FLT3 SOS1 GRB2 KDR PRKCA BRAF ARAF FLT4 PRKCA FLT1 PRKCA PDGFRB SOS1 PIK3CA Sfib Sfib Sfib KIT C P a R Apopt A o T F AKT Pat Apopt